Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Precigen Inc(PGEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PGEN
11/06/2026: PGEN (3-star) is currently NOT-A-BUY. Pass it for now.
Precigen is a clinical-stage biotechnology company focused on gene and cell therapies using its UltraCAR-T and AdenoVerse platforms. The company's main strength is its proprietary technology, which aims to provide faster, more efficient manufacturing for personalized cancer treatments. Its primary growth story revolves around successfully advancing these therapies through clinical trials to prove efficacy and safety. Key risks include significant ongoing cash burn, high competition from well-capitalized industry peers, and the inherent clinical and regulatory challenges of drug development. This stock is best suited for risk-tolerant investors looking for long-term growth; stakeholders should monitor upcoming clinical trial results and potential licensing developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Precigen offers high-risk, high-reward potential based on its clinical platform but lacks established revenue growth. |
| Momentum investor | Weak fit | The stock lacks sustained upward momentum and typically moves on binary clinical trial results. |
| Value investor | Weak fit | The company is a pre-revenue biotech with no earnings, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Precigen does not pay a dividend and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | The stock is highly volatile and carries significant clinical and financial risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to clinical trial outcomes and biotech sector sentiment. |
| Valuation risk | Medium / high | Valuation is speculative as it relies on future potential of pipeline assets rather than current cash flows. |
| Competition risk (CAR-T / Immunotherapy) | High | Established players have deeper resources for clinical trials and commercialization. |
| Business quality | Medium | The company has strong technology platforms but remains in the early stages of clinical validation. |
| Dividend income | Low / none | The company is in an early growth phase and does not provide income. |
| Execution risk | High | Successful transition from a platform developer to a developer of approved commercial products is inherently uncertain. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 97.23% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.60B USD | Price to earnings Ratio 40.64 | 1Y Target Price 13.65 |
Price to earnings Ratio 40.64 | 1Y Target Price 13.65 | ||
Volume (30-day avg) 6.8M shares | Beta 0.98 | 52 Weeks Range 3.04 - 8.98 | Updated Date 11/08/2026 |
52 Weeks Range 3.04 - 8.98 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.11 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research and Licensing | Collaborations, licensing of intellectual property, and developmental milestones from platform assets. | The company generates revenue primarily through research partnerships and licensing, not from product sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 0.09 | Actual 0.08 |
Profitability
Profit Margin 15.55% | Operating Margin (TTM) 52.13% |
Management Effectiveness
Return on Assets (TTM) 10.97% | Return on Equity (TTM) 38.84% |
Valuation
Trailing PE 40.64 | Forward PE 10.16 | Enterprise Value 1.66B | Price to Sales(TTM) 10.21 |
Enterprise Value 1.66B | Price to Sales(TTM) 10.21 | ||
Enterprise Value to Revenue 10.55 | Enterprise Value to EBITDA 40.5 | Shares Outstanding 358.55M | Shares Floating 195.12M |
Shares Outstanding 358.55M | Shares Floating 195.12M | ||
Percent Insiders 12.62 | Percent Institutions 72.78 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.